Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rang in Aktien #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Aktienkurs
$9.60
Zuletzt synchronisiert: 2025-05-21
Marktkapitalisierung
$1.08B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel OptiNose, Inc. (OPTN)

Kategorie

Gewinn für OptiNose, Inc. (OPTN)
Gewinn im Mar 2025 TTM: $-29.89M
Laut den aktuellen Finanzberichten von OptiNose, Inc. betragen die aktuellen Gewinne des Unternehmens $-29.89M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-35.48M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-74.83M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von OptiNose, Inc. von 2015 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-29.89M 38.76%
2024 $-21.54M -39.29%
2023 $-35.48M -52.58%
2022 $-74.83M -9.07%
2021 $-82.30M -17.53%
2020 $-99.79M -9.33%
2019 $-110.05M 3.18%
2018 $-106.66M 118.11%
2017 $-48.90M -316.26%
2016 $22.61M -179.87%
2015 $-28.31M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten